- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 509714, 12 pages
RNase P-Associated External Guide Sequence Effectively Reduces the Expression of Human CC-Chemokine Receptor 5 and Inhibits the Infection of Human Immunodeficiency Virus 1
1State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Hubei, Wuhan 430072, China
2Program in Comparative Biochemistry, University of California, Berkeley, CA 94720, USA
3School of Public Health, University of California, Berkeley, CA 94720, USA
Received 2 August 2012; Revised 17 October 2012; Accepted 25 October 2012
Academic Editor: Edouard Cantin
Copyright © 2013 Wenbo Zeng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- L. J. Scherer and J. J. Rossi, “Approaches for the sequence-specific knockdown of mRNA,” Nature Biotechnology, vol. 21, no. 12, pp. 1457–1465, 2003.
- S. W. Santoro and G. F. Joyce, “A general purpose RNA-cleaving DNA enzyme,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4262–4266, 1997.
- C. A. Stein and Y. C. Cheng, “Antisense oligonucleotides as therapeutic agents—is the bullet really magical?” Science, vol. 261, no. 5124, pp. 1004–1012, 1993.
- F. Wong-Staal, E. M. Poeschla, and D. J. Looney, “A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA,” Human Gene Therapy, vol. 9, no. 16, pp. 2407–2425, 1998.
- J. Zhou and J. J. Rossi, “Current progress in the development of RNAi-based therapeutics for HIV-1,” Gene Therapy, vol. 18, no. 12, pp. 1134–1138, 2011.
- J. Zu Putlitz, Q. Yu, J. M. Burke, and J. R. Wands, “Combinatorial screening and intracellular antiviral activity of hairpin ribozymes directed against hepatitis B virus,” Journal of Virology, vol. 73, no. 7, pp. 5381–5387, 1999.
- M. Yu, J. Ojwang, O. Yamada et al., “A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 13, pp. 6340–6344, 1993.
- N. Sarver, E. M. Cantin, P. S. Chang et al., “Ribozymes as potential anti-HIV-1 therapeutic agents,” Science, vol. 247, no. 4947, pp. 1222–1225, 1990.
- L. Wiebusch, M. Truss, and C. Hagemeier, “Inhibition of human cytomegalovirus replication by small interfering RNAs,” Journal of General Virology, vol. 85, no. 1, pp. 179–184, 2004.
- J. M. Jacque, K. Triques, and M. Stevenson, “Modulation of HIV-1 replication by RNA interference,” Nature, vol. 418, no. 6896, pp. 435–438, 2002.
- J. Chung, J. J. Rossi, and U. Jung, “Current progress and challenges in HIV gene therapy,” Future Virology, vol. 6, no. 11, pp. 1319–1328, 2011.
- V. Gopalan, A. Vioque, and S. Altman, “RNase P: variations and uses,” Journal of Biological Chemistry, vol. 277, no. 9, pp. 6759–6762, 2002.
- S. M. L. Raj and F. Liu, “Engineering of RNase P ribozyme for gene-targeting applications,” Gene, vol. 313, no. 1-2, pp. 59–69, 2003.
- D. Evans, S. M. Marquez, and N. R. Pace, “RNase P: interface of the RNA and protein worlds,” Trends in Biochemical Sciences, vol. 31, no. 6, pp. 333–341, 2006.
- V. Gopalan and S. Altman, “RNase P: structure and catalysis,” in The RNA World, R. Gesteland, T. Cech, and J. Atkins, Eds., chapter 6.1, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, 2006.
- A. C. Forster and S. Altman, “External guide sequence for an RNA enzyme,” Science, vol. 249, no. 4970, pp. 783–786, 1990.
- Y. Yuan, E. S. Hwang, and S. Altman, “Targeted cleavage of mRNA by human RNase P,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 17, pp. 8006–8010, 1992.
- D. Plehn-Dujowich and S. Altman, “Effective inhibition of influenza virus production in cultured cells by external guide sequences and ribonuclease P,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 13, pp. 7327–7332, 1998.
- D. Kawa, J. Wang, Y. Yuan, and F. Liu, “Inhibition of viral gene expression by human ribonuclease P,” RNA, vol. 4, no. 11, pp. 1397–1406, 1998.
- C. Guerrier-Takada, Y. Li, and S. Altman, “Artificial regulation of gene expression in Escherichia coli by RNase P,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 24, pp. 11115–11119, 1995.
- T. Zhou, J. Kim, A. F. Kilani et al., “In vitro selection of external guide sequences for directing RNase P-mediated inhibition of viral gene expression,” Journal of Biological Chemistry, vol. 277, no. 33, pp. 30112–30120, 2002.
- H. Li, P. Trang, K. Kim, T. Zhou, S. Umamoto, and F. Liu, “Effective inhibition of human cytomegalovirus gene expression and growth by intracellular expression of external guide sequence RNA,” RNA, vol. 12, no. 1, pp. 63–72, 2006.
- J. Zhu, P. Trang, K. Kim, T. Zhou, H. Deng, and F. Liu, “Effective inhibition of Rta expression and lytic replication of Kaposi's sarcoma-associated herpesvirus by human RNase P,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 24, pp. 9073–9078, 2004.
- G. Kraus, R. Geffin, G. Spruill et al., “Cross-clade inhibition of HIV-1 replication and cytopathology by using RNase P-associated external guide sequences,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 6, pp. 3406–3411, 2002.
- B. J. Doranz, J. F. Berson, J. Rucker, and R. W. Doms, “Chemokine receptors as fusion cofactors fat human immunodeficiency virus type 1 (HIV-1),” Immunologic Research, vol. 16, no. 1, pp. 15–28, 1997.
- E. A. Berger, “HIV entry and tropism: the chemokine receptor connection,” AIDS, vol. 11, supplement, pp. S3–S16, 1997.
- H. K. Deng, D. Unutmaz, V. N. Kewalramani, and D. R. Littman, “Expression cloning of new receptors used by simian and human immunodeficiency viruses,” Nature, vol. 388, no. 6639, pp. 296–300, 1997.
- F. Liao, H. H. Lee, and J. M. Farber, “Cloning of STRL22, a new human gene encoding a G-protein-coupled receptor related to chemokine receptors and located on chromosome 6q27,” Genomics, vol. 40, no. 1, pp. 175–180, 1997.
- E. A. Berger, P. M. Murphy, and J. M. Farber, “Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease,” Annual Review of Immunology, vol. 17, pp. 657–700, 1999.
- P. D. Bieniasz and B. R. Cullen, “Chemokine receptors and human immunodeficiency virus infection,” Frontiers in Bioscience, vol. 3, pp. 44–58, 1998.
- W. A. Paxton, S. R. Martin, D. Tse et al., “Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures,” Nature Medicine, vol. 2, no. 4, pp. 412–417, 1996.
- M. Samson, F. Libert, B. J. Doranz et al., “Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene,” Nature, vol. 382, no. 6593, pp. 722–726, 1996.
- R. Liu, W. A. Paxton, S. Choe et al., “Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection,” Cell, vol. 86, no. 3, pp. 367–377, 1996.
- N. L. Michael, L. G. Louie, and H. W. Sheppard, “CCR5-delta 32 gene deletion in HIV-1 infected patients,” The Lancet, vol. 350, pp. 741–742, 1997.
- M. Dean, M. Carrington, C. Winkler et al., “Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study,” Science, vol. 273, no. 5283, pp. 1856–1862, 1996.
- F. Buseyne, G. Janvier, J. P. Teglas et al., “Impact of heterozygosity for the chemokine receptor CCR5 32-bp-deleted allele on plasma virus load and CD4 T lymphocytes in perinatally human immunodeficiency virus-infected children at 8 years of age,” Journal of Infectious Diseases, vol. 178, no. 4, pp. 1019–1023, 1998.
- Y. Feng, M. Leavitt, R. Tritz et al., “Inhibition of CCR5-dependent HIV-1 infection by hairpin ribozyme gene therapy against CC-chemokine receptor 5,” Virology, vol. 276, no. 2, pp. 271–278, 2000.
- L. Cagnon and J. J. Rossi, “Downregulation of the CCR5 β-chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts,” Antisense and Nucleic Acid Drug Development, vol. 10, no. 4, pp. 251–261, 2000.
- J. Anderson and R. Akkina, “CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-I infection,” Retrovirology, vol. 2, article 53, 2005.
- E. Song, S. K. Lee, D. M. Dykxhoorn et al., “Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages,” Journal of Virology, vol. 77, no. 13, pp. 7174–7181, 2003.
- P. Lusso, F. Cocchi, C. Balotta et al., “Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1,” Journal of Virology, vol. 69, no. 6, pp. 3712–3720, 1995.
- A. M. Pyle, J. A. McSwiggen, and T. R. Cech, “Direct measurement of oligonucleotide substrate binding to wild-type and mutant ribozymes from Tetrahymena,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 21, pp. 8187–8191, 1990.
- A. D. Miller and G. J. Rosman, “Improved retroviral vectors for gene transfer and expression,” BioTechniques, vol. 7, no. 9, pp. 980–990, 1989.
- F. Liu and S. Altman, “Inhibition of viral gene expression by the catalytic RNA subunit of RNase P from Escherichia coli,” Genes and Development, vol. 9, no. 4, pp. 471–480, 1995.
- P. M. Daftarian, A. Kumar, M. Kryworuchko, and F. Diaz-Mitoma, “IL-10 production is enhanced in human T cells by IL-12 and IL-6 and in monocytes by tumor necrosis factor-α,” Journal of Immunology, vol. 157, no. 1, pp. 12–20, 1996.
- A. J. Zaug and T. R. Cech, “Analysis of the structure of Tetrahymena nuclear RNAs in vivo: telomerase RNA, the self-splicing rRNA intron, and U2 snRNA,” RNA, vol. 1, no. 4, pp. 363–374, 1995.
- Y. Yuan and S. Altman, “Selection of guide sequences that direct efficient cleavage of mRNA by human ribonuclease P,” Science, vol. 263, no. 5151, pp. 1269–1273, 1994.
- M. Sprinzl, N. Dank, S. Nock, and A. Schon, “Compilation of tRNA sequences and sequences of tRNA genes,” Nucleic Acids Research, vol. 19, supplement, pp. 2127–2171, 1991.
- J. M. Nolan, D. H. Burke, and N. R. Pace, “Circularly permuted tRNAs as specific photoaffinity probes of ribonuclease P RNA structure,” Science, vol. 261, no. 5122, pp. 762–765, 1993.
- D. Kahle, U. Wehmeyer, and G. Krupp, “Substrate recognition by RNase P and by the catalytic M1 RNA: identification of possible contact points in pre-tRNAs,” EMBO Journal, vol. 9, no. 6, pp. 1929–1937, 1990.
- F. Liu and S. Altman, “Differential evolution of substrates for an RNA enzyme in the presence and absence of its protein cofactor,” Cell, vol. 77, no. 7, pp. 1093–1100, 1994.
- E. Bertrand, D. Castanotto, C. Zhou et al., “The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization,” RNA, vol. 3, no. 1, pp. 75–88, 1997.
- M. Ma, L. Benimetskaya, I. Lebedeva, J. Dignam, G. Takle, and C. A. Stein, “Intracellular mRNA cleavage induced through activation of RNase P by nuclease-resistant external guide sequences,” Nature Biotechnology, vol. 18, no. 1, pp. 58–61, 2000.
- E. O. Freed and M. A. Martin, “HIVs and their replication,” in Fields Virology, D. M. Knipe, P. M. Howley, D. E. Griffin, et al., Eds., pp. 2108–2185, Lippincott-William & Wilkins, Philadelphia, Pa, USA, 2007.
- D. R. Kuritzkes and B. D. Walker, “HIV-1: pathogenesis, clinical manifestations, and treatment,” in Fields Virology, D. M. Knipe, P. M. Howley, D. E. Griffin, et al., Eds., pp. 2188–2214, Lippincott-William & Wilkins, Philadelphia, Pa, USA, 2007.
- R. Akkina, A. Banerjea, J. Bai, J. Anderson, M. J. Li, and J. Rossi, “siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS,” Anticancer Research, vol. 23, no. 3 A, pp. 1997–2005, 2003.
- D. S. Strayer, R. Akkina, B. A. Bunnell et al., “Current status of gene therapy strategies to treat HIV/AIDS,” Molecular Therapy, vol. 11, no. 6, pp. 823–842, 2005.
- B. Autran, G. Carcelain, T. S. Li et al., “Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease,” Science, vol. 277, no. 5322, pp. 112–116, 1997.
- P. Yeni, “Update on HAART in HIV,” Journal of Hepatology, vol. 44, no. 1, pp. S100–S103, 2006.
- F. J. Palella Jr., K. M. Delaney, A. C. Moorman et al., “Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection,” New England Journal of Medicine, vol. 338, no. 13, pp. 853–860, 1998.